Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CCR2 Antagonist · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | - |
| A2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CCR2 Antagonist | DRUG | Tablets, Oral, 50 mg, once daily, 12 weeks |
| Placebo | DRUG | Tablets, Oral, 0mg, once daily, 12 weeks |
Inclusion Criteria: * Drug-naive Type 2 diabetics with a screening HbA1c of ≥ 7.5% and ≤ 10% * Screening FPG ≥ 140 mg/dL and ≤ 220 mg/dL * BMI ≤ 40 kg/m2 Exclusion Criteria: * Active tuberculosis * Symptoms of poorly controlled diabetes * History of diabetic ketoacidosis * Significant cardiovascu...
Top 20 of 31 competitors
CCR2 Antagonist is an investigational small molecule being studied for the treatment of Type 2 Diabetes. It is being developed by Bristol-Myers Squibb Company (BMY) as a potential therapy for this metabolic condition. The drug has completed a Phase 2 clinical trial, but it is not yet approved and remains in clinical development.
CCR2 Antagonist targets the CCR2 receptor, which is involved in inflammatory processes. By blocking this receptor, the drug may help address insulin resistance, a key factor in Type 2 Diabetes. This mechanism was evaluated in a Phase 2 proof-of-concept study in patients with insulin resistance.
CCR2 Antagonist is being developed by Bristol-Myers Squibb Company, a biopharmaceutical company traded on the New York Stock Exchange under the ticker BMY. The company conducted a Phase 2 clinical trial of this drug in patients with Type 2 Diabetes.
CCR2 Antagonist is in Phase 2 clinical development. A Phase 2 trial, NCT00699790, has been completed. The drug is investigational and has not been approved by regulatory authorities. Its safety and efficacy are still being evaluated in clinical studies.
CCR2 Antagonist has one completed Phase 2 clinical trial, NCT00699790, titled 'Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance.' This randomized, double-blind, placebo-controlled trial enrolled 58 participants with Type 2 Diabetes in Russia. The trial is no longer active.
Yes, CCR2 Antagonist is also known as BMS-741672. The Phase 2 clinical trial NCT00699790 used this alternative name in its title. Both names refer to the same investigational drug being developed by Bristol-Myers Squibb for Type 2 Diabetes.